BRUSSELS (Reuters) – EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer Catalent, according to a filing on the European Commission website on Monday.
The controlling shareholder of Novo Nordisk put in a request for EU approval for the deal on Oct. 31, the filing showed.
The EU antitrust can either clear the deal with or without remedies or it can open a full-scale four-month long investigation if it has serious concerns.
(Reporting by Foo Yun Chee)
Brought to you by www.srnnews.com